Manufacturing chimeric antigen receptor T cells: issues and challenges
Clinical trials of adoptively transferred CD19 chimeric antigen receptor (CAR) T cells have
delivered unprecedented responses in patients with relapsed refractory B-cell malignancy.
These results have prompted Food and Drug Administration (FDA) approval of two CAR T-
cell products in this high-risk patient population. The widening range of indications for CAR
T-cell therapy and increasing patient numbers present a significant logistical challenge to
manufacturers aiming for reproducible delivery systems for high-quality clinical CAR T-cell …
delivered unprecedented responses in patients with relapsed refractory B-cell malignancy.
These results have prompted Food and Drug Administration (FDA) approval of two CAR T-
cell products in this high-risk patient population. The widening range of indications for CAR
T-cell therapy and increasing patient numbers present a significant logistical challenge to
manufacturers aiming for reproducible delivery systems for high-quality clinical CAR T-cell …
